medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2013, Número 4

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2013; 11 (4)


Carcinoma sebáceo: informe de un caso

Ismael Cheng FI, Sánchez AMEK

Idioma: Español
Referencias bibliográficas: 22
Paginas: 267-269
Archivo PDF: 144.41 Kb.


RESUMEN

Paciente masculino de 66 años con carcinoma cebáceo y patrón global inespecífico en la dermatoscopia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Herrero JE, Puig S, Malvehy J. “Utilidad de la microscopia de epiluminiscencia en el diagnóstico de tumores pigmentados no melanocíticos”. Piel 2001; 16: 209-306.

  2. Flores-Villa R, Magaña M. “Carcinoma sebáceo extraocular”. Actas Dermatol 2002; 2: 54-56.

  3. Valenzuela-Flores G, Mozas-Dávila D, Rodriguez-Reyes A, Gómez-Leal. “Carcinoma de glándulas sébaceas de los parpados”. Cir Ciruj 2004; 72: 47-53.

  4. González-Almaraz G. “Carcinoma Sebáceo”. Rev Cent Dermatol 1999; 8: 76-85.

  5. Kass LG, Hornblass A. “Sebaceous carcinoma of the ocular adnexa”. Surv Ophthalmol 1989; 33: 477-490.

  6. Dowd MB, Kumar RJ, Sharma R, Murali R. “Diagnosis and management of sebaceous carcinoma: an Australacian experience”. ANZ J Surg 2008; 78: 158-163.

  7. Mirzamani N, Sundram UN. “A case of sebaceous carcinoma diagnosed in an adolescent male”. J Cutan Pathol 2011; 38: 435-438.

  8. Mebazza A, Boussofara L, Trabelsi A, Denguezl M, et al. “Undifferentiated sebaceous carcinoma: an unusual childhood cancer”. Pediat Dermatol 2007; 24: 501-504.

  9. Eisen BD, Daniel J. “Sebaceous lesions and their associated syndromes: Part I”. J Am Acad Dermatol 2009; 61: 549-557.

  10. Heyl J, Mehregan D. “Inmunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas”. J Cutan Pathol 2008; 35: 40-45.

  11. Sranek B, Lisle A, Loy T. “Immunohistochemistry in ocular carcinomas”. J Cutan Pathol 2008; 35: 641-646.

  12. Cabral SE, Auerbach A, Killian JK, et al. “Distinction of Benign Sebaceous Proliferations From Sebaceous Carcinomas by Immunohistochemistry”. Am J Dermatopathol 2006; 28: 465-471.

  13. Halsey MA, Clder KA, Mathew R, Schalauder S, Morgan MB. “Expression of α-methylacyl-CoA racemase (P504s) in sebaceous neoplasm”. J Cutan Pathol 2007; 37: 446-451.

  14. Buitrago W, Joseph AK. “Sebaceous carcinoma: the great masquerader emerging concepts in diagnosis and tratment”. Dermatol Ther 2008; 21: 459-466.

  15. Carli P, De Georgi V, Stante M, et al. “Dermatoscopy in the diagnosis of pigmented skin lesions: a new semilogy for the dermatologist”. J Eur Acad Dermatol Venerol 2000; 14: 353-369.

  16. Oztas P, Polat M, Oztas M, Alli N, et al. “Bonbon toffe sing: a new dermatoscopic feature for sebaceous hypelplasia”. J Eur Acad dermatol Venerol 2008; 22: 1200-1202.

  17. Mangold E, Pangestercher C, Mathiak M, et al. “A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome”. J Med Genet 2004; 41: 567-572.

  18. Graham R, McKee P, McGibbon D, Torre-Muir. “Syndrome an association with isolated sebaceous carcinoma”. Cancer 1985; 15: 2868-2873.

  19. Dasgupta T, Wilson LD, Yu JB. “A retrospective review of 1349 cases of sebaceous carcinoma”. Cancer 2009; 115: 158-165.

  20. Hasebe T, Mukai K, Ishihara K, et al. “Sebaceous Gland and sweat gland carcinomas of the skin clinicopathological study and significance of c-erbB-2 oncoprotein expression”. Acta Pathol Jpn 1992; 8: 585-594.

  21. Dowd M, Kumar R, Sharma R, Murali R. “Diagnosis and management of sebaceous carcinoma: An asutralian experience”. AZN J Surg 2008; 78: 158-163.

  22. Thosani MK, Marghoob A, et al. “Current progress of immunostains in Mohs micrographic surgery: a review”. Dermatol Surg 2008; 34: 1621-1636.




2020     |     www.medigraphic.com